Protocol Ledger

NCT05540327 · Phase II · ACTIVE NOT RECRUITING

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

Interventional Phase II clinical trial protocol NCT05540327 sponsored by EMD Serono / Merck KGaA in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-09-16 Enrollment: 381 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05540327
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)381 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05540327
Protocol FieldVerified Registry Value
NCT IdentifierNCT05540327
Consolidated Lead SponsorEMD Serono / Merck KGaA
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment381 participants (ACTUAL)
Registered Start Date2022-09-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05540327
Hospital Research SiteLocationSite Profile
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->
University of MinnesotaMinneapolis, MNOpen Hospital Dossier ->
Ohio State University Comprehensive Cancer CenterColumbus, OHOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI